Chronic Lymphocytic Leukemia

rise-of-molecular-glues

Jan 10, 2025

The Rise of Molecular Glues: Transforming Protein-Protein Interactions into Therapeutic Opportunities

Dec 12, 2023

Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment

jaypirca-for-chronic-lymphocytic-leukemia

Dec 11, 2023

Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

Latest Pharma News and Updates for BeiGene, Seagen, Alnylam, Roche, Astellas

Jan 24, 2023

BeiGene’s Brukinsa Approval; FDA Approval to Seagen’s TUKYSA; NICE Recommends Alnylam’s Amvuttra; FDA Approves Brenzavvy for Type 2 Diabetes; Roche’s Tecentriq to be Filed for Early-stage Liver Cancer; FDA Lifts Hold on Astellas’ Pompe Gene Therapy

pharma-news

Jun 09, 2020

Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper